Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
RESEARCH TOOLSreports
Holding DAWN?
Track your performance easily
Earnings Data
Report Date
Mar 10, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.46Last Year’s EPS
-$0.63Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 30, 2024
|% Change Since: -11.61%
|Next Earnings Date:Mar 10, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong positive tone with significant revenue growth from the successful launch of OJEMDA, substantial financial strength, and progress in pipeline expansion. However, increased operating expenses and expected challenges in market penetration were noted.Company Guidance
During Day One Biopharmaceuticals' Q3 2024 earnings call, several key metrics were highlighted to demonstrate the company's progress and future strategies. Notably, OJEMDA, their recently launched product, generated $20.1 million in net product revenue for the quarter, marking a 145% increase from the previous quarter. This success was attributed to over 850 total prescriptions and high payer approval rates. The median duration of response for patients in a specific trial arm extended from 13.8 months to 18 months, reflecting the drug's efficacy. The company also reported a strong financial position with $558.4 million in cash, reinforcing their capability to fund future operations and expand their portfolio in 2025. The call further emphasized strategic partnerships, like the ex-U.S. collaboration with Ipsen, and anticipated progress in clinical trials, specifically the upcoming dosing in the Phase I trial of DAY301.OJEMDA Revenue Growth
OJEMDA net product revenue for Q3 was $20.1 million, more than double the previous quarter, indicating strong commercial execution.
Successful Launch of OJEMDA
In the first five months since approval, OJEMDA generated $28.3 million in net revenues, with over 850 total prescriptions and high payer approval rates.
Expansion and Pipeline Progress
Day One is on track to dose the first patients in the Phase I trial of DAY301 by Q4 this year or early Q1 next year, expanding their portfolio with a PTK7 targeted ADC.
Financial Strength
Day One is in a strong financial position with over $0.5 billion in cash, allowing for funding of operating plans and portfolio expansion in 2025.
Ex-U.S. Partnership and Licensing Revenue
Day One licensed ex-U.S. commercial rights of tovorafenib to Ipsen, contributing $73.7 million in license revenue in Q3 2024.
---
DAWN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DAWN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | $14.47 | $14.72 | +1.73% |
| Jul 30, 2024 | $15.36 | $15.19 | -1.11% |
| May 06, 2024 | $16.60 | $17.08 | +2.89% |
| Feb 26, 2024 | $15.65 | $17.38 | +11.05% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Day One Biopharmaceuticals (DAWN) report earnings?
Day One Biopharmaceuticals (DAWN) is schdueled to report earning on Mar 10, 2025, TBA Not Confirmed.
What is Day One Biopharmaceuticals (DAWN) earnings time?
Day One Biopharmaceuticals (DAWN) earnings time is at Mar 10, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DAWN EPS forecast?
DAWN EPS forecast for the fiscal quarter 2024 (Q4) is -$0.46.
---